Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 371 to 380 of 1334 total matches.

Epoprostenol for Primary Pulmonary Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996  (Issue 968)
, some for as long as nine years, have returned to normal activities, including school and work. DOSAGE ...
Epoprostenol sodium (Flolan - Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension.
Med Lett Drugs Ther. 1996 Feb 16;38(968):14-5 |  Show IntroductionHide Introduction

Azelaic Acid - A New Topical Drug for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996  (Issue 976)
). The antibiotics and benzoyl peroxide are active against Propionibacterium acnes, the bacteria thought ...
Azelaic acid, a naturally occurring heptanedicarboxylic acid, has been marketed in the USA as a 20% cream (Azelex - Allergan) for treatment of acne. The drug has been available in Europe for several years.
Med Lett Drugs Ther. 1996 Jun 7;38(976):52-3 |  Show IntroductionHide Introduction

Bicalutamide for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
, inhibits the uptake and binding of androgens, including dihydrotestosterone, the active form ...
Bicalutamide (Casodex - Zeneca), an oral nonsteroidal antiandrogen similar to flutamide (Eulexin - Medical Letter, 31:72, 1989), is now available in the USA for treat-ment of advanced prostate cancer. The drug is recommended by the manufacturer for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot) or goserelin (Zoladex -Medical Letter, 32:102, 1990).
Med Lett Drugs Ther. 1996 Jun 21;38(977):56-7 |  Show IntroductionHide Introduction

Interferon Beta-1a for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996  (Issue 979)
in 301 ambulatory patients with active relapsing MS and minimal disability. Among the patients followed ...
Interferon β-1a (Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a (Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Med Lett Drugs Ther. 1996 Jul 19;38(979):63-4 |  Show IntroductionHide Introduction

Zinc for the Common Cold

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
and health food stores throughout the USA. ANTIVIRAL ACTIVITY — In vitro zinc has some non-selective ...
Results of a recent study suggested that zinc gluconate may be effective in treating the common cold (SB Mossad et al, Ann Intern Med, 125:81, July 15, 1996). Zinc gluconate lozenges, sometimes combined with vitamin C or other ingredients, are available in pharmacies and health food stores throughout the USA.
Med Lett Drugs Ther. 1997 Jan 31;39(993):9-10 |  Show IntroductionHide Introduction

Arbutamine for Stress Testing

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998  (Issue 1019)
-adrenoreceptor agonist with alpha 1 agonist activity (M Young et al, Drug Dev Res, 32:19, 1994). It increases ...
Myocardial perfusion imaging and stress echocardiography in patients who cannot exercise may require use of drugs. Arbutamine (GenESA - Gensia Automedics), a potent synthetic sympathomimetic, has recently been approved by the FDA for use with a computerized drug-delivery system in pharmacologic stress testing.
Med Lett Drugs Ther. 1998 Jan 30;40(1019):19-20 |  Show IntroductionHide Introduction

Raloxifene for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998  (Issue 1022)
density in the lumbar spine, hip and femoral neck decreased with placebo and increased with the active ...
Raloxifene (Evista - Lilly), a benzothiophene that acts on estrogen receptors, has recently been marketed for prevention of postmenopausal osteoporosis. Only estrogen (alone or in combination with a progestin) and the bisphosphonate alendronate (Fosamax) were previously approved by the FDA for this indication.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):29-30 |  Show IntroductionHide Introduction

Sibutramine for Obesity

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998  (Issue 1022)
. The demethylated metabolites, which are active, are then conjugated and hydrolyzed to inactive metabolites, also ...
Sibutramine hydrochlorid monohydreate (Meridia - Knoll), which is structurally related to amphetamine, has been approved by the FDA for treatment of obesity. It is classified by the Drug Enforcement Agency (DEA) as a schedule IV controlled substance.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):32 |  Show IntroductionHide Introduction

Prosorba Column for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999  (Issue 1058)
, activation of complement and an increase in T-cell activity (FS Morrison and DW Huestis, J Clin Apheresis, 7 ...
Prosorba, an antibody-adsorbing column used with plasmapheresis, has been approved by the FDA for treatment of moderate-to-severe rheumatoid arthritis in patients refractory or intolerant to methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs).
Med Lett Drugs Ther. 1999 Jul 30;41(1058):67-70 |  Show IntroductionHide Introduction

Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010  (Issue 1344)
Table 1. Pharmacology of Inhaled Aztreonam Class Monobactam antibiotic Activity In vitro activity ...
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
Med Lett Drugs Ther. 2010 Aug 9;52(1344):63-4 |  Show IntroductionHide Introduction